Claims
- 1. A cleansing composition for a human or other land animal, comprising:
A. a cleanser selected from the goup consisting of soaps, surfactants, detergents, and mixtures thereof; and B. an effective amount of a natural EGFR inhibitor.
- 2. The cleanser of claim 1, wherein the EGFR inhibitor is present in an amount between 0.1% and 10% by weight.
- 3. The cleanser of claim 2, wherein the EGFR inhibitor is present in an amount between 1% and 7% by weight.
- 4. The cleanser of claim 1, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole, staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 5. The cleanser of claim 4, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, and mixtures thereof.
- 6. The cleanser of claim 4, wherein the inhibitor is provided as a ground or powdered soy (soya) product, including soy bean.
- 7. The cleanser of claim 1, wherein the cleanser is a cleanser for use on animals.
- 8. A composition for dermatitis presenting as hyperproliferation of skin cells on the hands caused by activation of the EGF, comprising a natural inhibitor of EGFR and a dermatologically suitable carrier therefor.
- 9. The composition of claim 8, wherein the inhibitor is an isoflavone.
- 10. The composition of claim 8, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 11. The composition of claim 10, wherein the inhibitor is genistein and is derived from a soy product.
- 12. The composition of claim 10, wherein the inhibitor is genistein or quercetin or both.
- 13. A method for for alleviating dermatitis presenting as hyperproliferation of skin cells on the hands, comprising: administering to the skin of an affected person's hand an amount of a natural inhibitor of EGFR effective to decrease EGFR activity, said EGFR inhibitor administered topically in a dermatologically suitable carrier.
- 14. The method of claim 13, wherein the hyperproliferation is due to chemical contact on the hand.
- 15. The method of claim 14, wherein the hyperproliferation is due to the use of a cleanser.
- 16. The method of claim 13, wherein the inhibitor is an isoflavone.
- 17. The method of claim 13, wherein the inhibitor is selected from the group consisting of genistein, quercetin, equol, indolecarbazole staurosporine, lavendustin, daidzein, and erbstatin, and mixtures thereof.
- 18. The method of claim 13, wherein the inhibitor is genistein or quercetin.
- 19. The method of claim 18, wherein the inhibitor is genistein and is derived from a soy product.
PRIOR APPLICATIONS
[0001] This application is a divisional of application Ser. No. 10/085,978, filed Feb. 27, 2002, which is on prior provisional application No. 60/271,894, filed Feb. 27, 2001, the disclosures of which are both incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60271894 |
Feb 2001 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10085978 |
Feb 2002 |
US |
Child |
10639160 |
Aug 2003 |
US |